Two cases of gigantism with divergent long-term outcomes: the impact of genetics and treatment adherence.
文献摘要
Gigantism is a rare disorder caused by growth hormone excess before epiphyseal closure. Long-term follow-up data are limited, particularly regarding the influence of genetic background and treatment adherence on disease outcomes. We report two adolescents diagnosed with gigantism during puberty who were followed at a tertiary endocrinology center for 12 and 21 years, respectively. Diagnosis was established based on elevated insulin-like growth factor 1 levels, failure of growth hormone suppression during oral glucose tolerance testing, and pituitary magnetic resonance imaging findings. Case l,a 14-year-old female, presented with accelerated linear growth, whereas Case 2, a 14-year-old male, was diagnosed following an orthopedic complication. Both patients had pituitary macroadenomas and underwent transsphenoidal surgery followed by treatment with somatostatin analogs. Germline genetic analysis of the AIP and MEN1 genes was performed using Sanger sequencing of coding exons and flanking regions from DNA extracted from peripheral blood leukocytes. One patient achieved sustained biochemical and structural remission after surgery and long-term somatostatin analog therapy, leading to treatment discontinuation. The other patient exhibited poor treatment adherence, persistent hormonal hypersecretion, residual tumor, and progressive systemic complications. Genetic analysis identified a pathogenic germline AIP nonsense variant (c.804C>A; p.Tyr268*) in the patient with unfavorable clinical evolution, whereas no pathogenic variants were detected in the other case. These findings illustrate divergent clinical trajectories in gigantism and highlight the combined impact of genetic background and treatment adherence on long-term outcomes, supporting the importance of genetic evaluation and sustained follow-up in early-onset disease.